Research
Hormonal
GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual agonists (Tirzepatide) provide superior weight loss and metabolic benefits compared to older agents like Orlistat or Phentermine, with Semaglutide and Tirzepatide showing the highest efficacy.
Newer injectable medications like Semaglutide and Tirzepatide are significantly more effective for weight loss than older oral drugs like Orlistat. Tirzepatide, in particular, has shown high efficacy in trials, with many users losing 15-20% of their body weight. These are weekly injections and are generally well-tolerated, though gastrointestinal side effects are common during dose escalation.
StrongSupportsHIGH confidence
The newest agents, and those in clinical development, are associated with considerably greater mean efficacy than older agents... Results from a phase 3 clinical trial for obesity... showed that tirzepatide 5 mg, 10 mg and 15 mg resulted in mean placebo- subtracted weight loss over 72 weeks of 11.9%, 16.4% and 17.8% respectively
Why this rating
Based on phase 3 trials and regulatory approvals.
Source
Current and emerging medications for the management of obesity in adults
Rosalind Walmsley et al. · The Medical Journal of Australia · 2023
narrative_reviewCited 19×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →